What will Dr. John Krakauer do as a strategic advisor to MindMaze Therapeutics?

Dr. John Krakauer will provide counsel as MindMaze Therapeutics scales in the United States, according to CEO Zach Henderson. The company said his advisory role would also keep him closely engaged in advancing the underlying research.

Why does MindMaze Therapeutics say Dr. John Krakauer is significant to its platform?

MindMaze Therapeutics said Dr. John Krakauer is the original scientific creator of MindPod®, its precision upper-limb rehabilitation system. The company also said his foundational work on the high-dose, high-intensity paradigm provides the scientific basis of its platform.

What did MindMaze Therapeutics report from its two-year real-world evidence programme?

MindMaze Therapeutics said its two-year, multi-site real-world evidence programme demonstrated significant improvements in patient mobility and self-care. It also reported a 60% increase in delivered therapy per day and 17% higher community discharge rates compared to standard of care.

What proportion of patients found MindMaze Therapeutics’ neurotherapy enjoyable?

MindMaze Therapeutics said 87% of patients found its neurotherapy enjoyable. This figure was included among the company’s reported results from its two-year, multi-site real-world evidence programme.

What does MindMaze Therapeutics say about the role of high-dose, high-intensity neurorehabilitation?

Dr. John Krakauer said the clinical case for high-dose, high-intensity neurorehabilitation is now unambiguous and that recovery depends on delivering the right dose and intensity of training. He said health systems have historically struggled to provide this consistently across care settings, including the home.

Where is MindMaze Therapeutics expanding its operations in the United States?

MindMaze Therapeutics has established a U.S. headquarters and Patient Experience Center at The Pearl, Charlotte’s Innovation District. The company linked this development to its next phase of growth in the United States.

What partnership has MindMaze Therapeutics announced?

MindMaze Therapeutics announced a go-to-market partnership with Vibra Healthcare earlier this year. The announcement did not provide further terms of the partnership.

What does MindMaze Therapeutics do?

MindMaze Therapeutics describes itself as a provider of scalable, precision neurotherapeutics. It integrates advanced software, proprietary sensors and AI-driven data analytics to provide care from the acute hospital phase through outpatient treatment and home-based therapy.

Which conditions does MindMaze Therapeutics say its products address?

MindMaze Therapeutics said its FDA-listed and CE-marked products are designed to address stroke, Parkinson’s disease and other neurological disorders. The company said the products are intended to offer scalable, reimbursable solutions in response to a shortage of specialised clinicians.

Where are MindMaze Therapeutics’ shares traded and what is the ticker symbol?

MindMaze Therapeutics is listed on SIX under the ticker symbol MMTX, written in the source as “SIX: MMTX”.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze Therapeutics appoints John Krakauer as strategic advisor

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze Therapeutics appoints John Krakauer as strategic advisor

Published Wednesday, 12 August 2026, 05:00 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Management change
Published: Wednesday, 12 August 2026, 05:00 AM
Source announcement: eqs-news.com

Key figures
Measure	Figure	Period	Compared with
Increase in delivered therapy per day	60%	a two-year, multi-site real-world evidence (RWE) program	Not stated
Community discharge rates	17% higher	a two-year, multi-site real-world evidence (RWE) program	17% higher vs standard of care

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics Holding SA (SIX: MMTX) announced on August 12, 2026, that Prof. John W. Krakauer has joined the Company as a strategic advisor. The company said his role will support its next phase of growth in the United States.

Prof. John W. Krakauer is the original scientific creator of MindPod®, MindMaze Therapeutics’ precision upper-limb rehabilitation system. He holds the John C. Malone Professorship in Neurology, Neuroscience, and Physical Medicine and Rehabilitation at The Johns Hopkins University School of Medicine, and directs the BLAM Lab and Centre for Restorative Neurotechnology. The announcement also identifies his work in motor neuroscience, stroke recovery, and neurorehabilitation as part of the scientific basis of the MindMaze platform.

Investor FAQs

MindMaze Therapeutics announced that Dr. John Krakauer had joined the company as a strategic advisor. The company said he would support its next phase of growth in the United States.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
Published: Wednesday, 12 August 2026, 05:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…